Hutchison China Meditech Limited Change of Non-executive Directors (9555F)
02 August 2016 - 5:18PM
UK Regulatory
TIDMHCM
RNS Number : 9555F
Hutchison China Meditech Limited
02 August 2016
Change of Non-executive Directors
London: Tuesday, August 2, 2016: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect
from August 1, 2016, Dr Dan Eldar has been appointed as a
Non-Executive Director of Chi-Med in place of Mr Salbaing who has
tendered his resignation to spend more time on his existing
responsibilities within the CK Hutchison Holdings Group.
Dr Eldar (formerly Perlmutter), aged 63, has more than 35 years
of experience as a senior executive, leading global operations in
telecommunications, water, biotech and healthcare. He is an
executive director of Hutchison Water Israel Ltd which focuses on
large scale projects including desalination, wastewater treatment
and water reuse. He is also an independent non-executive director
of Leumi Card, a subsidiary of Bank Leumi Le-Israel B.M., one of
Israel's leading credit card companies. Further, he is also a
director of Aqua Blue Water Management Services Ltd, Hutchison
Biofilm Medical Solutions Holdings Limited, Hutchison Biofilm
Medical Solutions Inc., Hutchison Biofilm Medical Solutions
Limited, Hutchison Biofilm Solutions Limited, Hutchison Water
General Partner Ltd, Hutchison Water Israel E.P.C. Ltd, TACount
Exact Ltd and Yissumim Advanced Management Application Ltd. Dr
Eldar was previously a director of WeFindTech Ltd. and Gryphonel
Ltd within the past five years.
Dr Eldar holds a Doctor of Philosophy degree in Government from
Harvard University, Master of Arts degree in Government from
Harvard University, Master of Arts degree in Political Science and
Public Administration from Hebrew University of Jerusalem and a
Bachelor of Arts degree in Political Science from Hebrew University
of Jerusalem.
He does not have any shareholdings in Chi-Med. Save for the
information disclosed above, there is no other information in
relation to Dr Eldar required to be disclosed pursuant to Rule 17
and Schedule 2(g) of the AIM Rules for Companies.
Mr Christian Hogg, Chief Executive Officer of Chi-Med said "We
thank Mr Salbaing for his invaluable contributions during his
tenure and welcome Dr Eldar to the Board whose experience in the
global high tech and biotech industries will be important to
Chi-Med."
NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative China-based biopharmaceutical company
which researches, develops, manufactures and sells pharmaceuticals
and healthcare products. Its Innovation Platform, Hutchison
MediPharma Limited, focuses on discovering and developing
innovative therapeutics in oncology and autoimmune diseases for the
global market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med!|s current expectations regarding future
events. Forward-looking statements involve risks and uncertainties.
Such risks and uncertainties include, among other things, the risk
that current or future appointees to Chi-Med's board of directors
are not effective in their respective positions, the difficulty in
locating and recruiting suitable candidates for its board of
directors and the management difficulties which may arise from
changes in Chi-Med's board of directors. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
For further discussion of these and other risks, see Chi-Med's
filings with the U.S. Securities and Exchange Commission and on
AIM. Chi-Med undertakes no obligation to update or revise the
information contained in this announcement, whether as a result of
new information, future events or circumstances or otherwise.
CONTACTS
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Brian Korb, The Trout Group +1 (917) 653 5122 (Mobile) bkorb@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASSWSWEFMSEFA
(END) Dow Jones Newswires
August 02, 2016 03:18 ET (07:18 GMT)